Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2025 16:30 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
March 24, 2025 16:20 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs),...
February 25, 2025 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Participate in Upcoming March Conferences

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
February 11, 2025 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide...
November 12, 2024 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings from...
November 07, 2024 10:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from...
September 04, 2024 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces Changes to its Board of Directors

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
August 28, 2024 07:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Participate in Upcoming September Conferences

REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
August 13, 2024 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society...
May 14, 2024 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further...